Core Viewpoint - Desay SV Automotive has launched its Chuanxing Zhiyuan S6 series of low-speed unmanned vehicles, which have garnered significant attention and received customer orders [1] Group 1: Product Launch - The Chuanxing Zhiyuan S6 series of low-speed unmanned vehicles has been released [1] - The product launch has attracted widespread attention from the market [1] - The company has received related customer orders for the new vehicle series [1] Group 2: Supply Capabilities - Desay SV Automotive has intelligent driving domain control products available for supply to unmanned logistics companies [1]

Core Viewpoint - Xiamen Tungsten Co., Ltd. has approved changes to its fundraising projects, reallocating remaining funds to new initiatives [1] Group 1: Company Decisions - The company held its 24th meeting of the 10th Board of Directors on February 10, 2026, where the proposal to change certain fundraising projects was unanimously approved with 9 votes in favor [1] - The original fundraising project for the "100 billion meters of tungsten wire production line for photovoltaic use" will undergo changes in investment amount, implementation locations, and construction period [1] Group 2: Fund Allocation - The remaining raised funds amounting to 58 million yuan will be redirected to new projects, including the "hard surface material expansion project," "CNC blade substrate expansion project," and "metal cutting solution engineering center project" [1]

格隆汇2月10日丨融捷股份(002192.SZ)公布，近日，公司董事会收到谢晔根先生提交的书面辞职报告。 因个人原因，谢晔根先生申请辞去公司首席执行官（CEO）职务，其原定任职期间为2025年11月11日至 公司第九届董事会届满之日（2028年11月10日）止。根据《公司法》《公司章程》等有关规定，其辞职 报告自送达公司董事会之日起生效。谢晔根先生辞去公司首席执行官（CEO）职务后，仍继续担任公司 第九届董事会董事。 ...

格隆汇2月10日丨恺英网络(002517.SZ)公布，2026年2月10日，公司以集中竞价交易方式首次回购股 份，回购股份数量206.1万股，占公司总股本的0.10%，其中，最高成交价为24.58元/股，最低成交价为 23.78元/股，成交总金额为4997.97万元（不含交易费用），本次回购符合相关法律法规的要求，符合既 定的回购方案。 ...

Core Viewpoint - The company is committed to implementing the national innovation-driven development strategy by addressing key issues in its southwestern industrial cluster, including the decentralization of R&D platforms, insufficient attraction of high-end talent, and the need to enhance innovation capabilities [1] Group 1 - The company plans to establish a Southwestern R&D center in Chengdu [1] - The total investment for the project is estimated at 99.298 million yuan [1] - The construction period for the R&D center is projected to be 18 months [1]

格隆汇2月10日丨中钨高新(000657.SZ)公布，为满足中钨高新西南研发中心建设项目资金需求，董事会 同意公司与自贡市国有资本投资运营集团有限公司按原股比共同向自贡硬质合金有限责任公司（简称自 硬公司）增资9,000万元，增资完成后自硬公司注册资本将由87,276.53万元变为96,276.53万元。 ...

格隆汇2月10日丨彤程新材(603650.SH)公布，公司已于2026年2月6日向香港联合交易所有限公司 （称"香港联交所"）递交了发行境外股份（H股）并在香港联交所主板挂牌上市（称"本次发行并上 市"）的申请，并于2026年2月8日在香港联交所网站刊登了本次发行并上市的申请资料。 ...

Core Viewpoint - The company, HaiMuxing (688559.SH), reported a significant change in shareholding by its shareholder, Tai'an Haihe Henghui No. 2 Investment Partnership, which has reduced its stake in the company, impacting the overall shareholding structure [1] Summary by Relevant Sections - **Shareholder Activity** - Tai'an Haihe reduced its shareholding by 1,572,000 shares from 12,234,000 shares to 10,662,000 shares between December 23, 2025, and February 10, 2026 [1] - This reduction led to a decrease in the shareholding percentage from 27.55% to 26.92% [1]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]

格隆汇2月10日丨中钨高新(000657.SZ)公布，为进一步扩大PCB钻针棒市场占有率、保障公司PCB刀具 原料需求、巩固公司PCB刀具全产业链龙头地位，董事会同意株洲硬质合金集团有限公司（简称株硬公 司）以1.45亿元实施新增PCB钻针棒3,000万支/年项目，建设期12个月。 ...